Brief: Rafael Pharmaceuticals Crosses Halfway Enrollment Point In Phase 3 Trial Of Cpi-613®️ To Treat Metastatic Pancreatic Cancer

Rafael Holdings

14/01/2020 14:26

Jan 14 (Reuters) - Rafael Holdings Inc  RFL.N :
    * RAFAEL PHARMACEUTICALS CROSSES HALFWAY ENROLLMENT POINT IN
PIVOTAL PHASE 3 TRIAL (AVENGER 500) OF CPI-613®️ (DEVIMISTAT)
FOR PATIENTS WITH METASTATIC PANCREATIC CANCER
    * RAFAEL PHARMACEUTICALS - REACHED ENROLLMENT MILESTONE OF
OVER
250 PATIENTS IN PHASE 3 CLINICAL TRIAL FOR METASTATIC PANCREATIC
CANCER (AVENGER 500)

Source text for Eikon:  ID:nGNX7mjD8g 
Further company coverage:  RFL.N 

 ((Reuters.Briefs@thomsonreuters.com;))